Amplia Therapeutics (ATX) Price & Analysis

Q: What was Amplia Therapeutics Ltd.’s price range in the past 12 months?

Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.

Q: What is Amplia Therapeutics Ltd.’s market cap?

Amplia Therapeutics Ltd.’s market cap is AU$64.13M.

Q: When is Amplia Therapeutics Ltd.’s upcoming earnings report date?

Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 160 days.

Q: How were Amplia Therapeutics Ltd.’s earnings last quarter?

Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.

Q: Is Amplia Therapeutics Ltd. overvalued?

According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Amplia Therapeutics Ltd. pay dividends?

Amplia Therapeutics Ltd. does not currently pay dividends.

Q: What is Amplia Therapeutics Ltd.’s EPS estimate?

Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Amplia Therapeutics Ltd. have?

Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.

Q: What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?

Amplia Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.

Q: Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATX

Compare

22 Followers

ATX Stock Chart & Stats

AU$0.14

<AU$0.01(2.33%)

At close: Jan 09 4:00 PM EST

AU$0.14

<AU$0.01(2.33%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.43

Previous CloseN/A

Volume274.48K

Average Volume (3M)513.42K

Market Cap

AU$64.13M

Enterprise ValueAU$0.00

Total Cash (Recent Filing)AU$29.16M

Total Debt (Recent Filing)AU$381.42K

Price to Earnings (P/E)―

Beta0.77

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding513,071,660

10 Day Avg. Volume413,994

30 Day Avg. Volume513,419

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)1.02

Price to Sales (P/S)5.68

P/FCF Ratio-3.12

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.03

Revenue Forecast (FY)N/A

Amplia Therapeutics News

Amplia Deepens Next & Bio Collaboration to Test Narmafotinib–kRAS Combo in Pancreatic Cancer

Amplia Therapeutics ( ($AU:ATX) ) has shared an announcement. Amplia Therapeutics has entered a second phase of its...

5d ago

Amplia Therapeutics Reports Positive ACCENT Trial Results for Pancreatic Cancer

The latest announcement is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics announced a positive development in...

12d ago

Amplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug

An announcement from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia Therapeutics has announced its financial report...

26d ago

Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial

The latest update is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics has received positive feedback from...

1M ago

Amplia Therapeutics Issues New Equity Securities

The latest update is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics Limited has announced the issuance...

1M ago

Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing

Amplia Therapeutics ( ($AU:ATX) ) has shared an announcement. Amplia Therapeutics has commenced trading on the U.S. OTCQB...

2M ago

Amplia Therapeutics Advances Narmafotinib Trials with Promising Results

An announcement from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia Therapeutics has reported significant progress in...

2M ago

Amplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials

Amplia Therapeutics ( ($AU:ATX) ) just unveiled an update. Amplia Therapeutics has received a $3.77 million R&D tax...

2M ago

Amplia Therapeutics’ Promising Study on Narmafotinib for Pancreatic Cancer

Amplia Therapeutics Ltd. (($INNMF)) announced an update on their ongoing clinical study. Amplia Therapeutics Ltd. is conducting a...

2M ago

INNMF

Amplia Therapeutics Expands U.S. Presence with New Investor Campaign

Amplia Therapeutics ( ($AU:ATX) ) has provided an update. Amplia Therapeutics is expanding its U.S. presence by increasing...

2M ago

ATX FAQ

What was Amplia Therapeutics Ltd.’s price range in the past 12 months?

Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.

What is Amplia Therapeutics Ltd.’s market cap?

Amplia Therapeutics Ltd.’s market cap is AU$64.13M.

When is Amplia Therapeutics Ltd.’s upcoming earnings report date?

Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 160 days.

How were Amplia Therapeutics Ltd.’s earnings last quarter?

Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.

Is Amplia Therapeutics Ltd. overvalued?

According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Amplia Therapeutics Ltd. pay dividends?

Amplia Therapeutics Ltd. does not currently pay dividends.

What is Amplia Therapeutics Ltd.’s EPS estimate?

Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Amplia Therapeutics Ltd. have?

Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.

What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?

Amplia Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.

Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Amplia Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-27.39%

Trailing 12-Months

Asset Growth

199.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amplia Therapeutics Ltd.

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.